R94
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 58
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.200
- ESTROGEN_RESPONSE_EARLY+0.180
- HEDGEHOG_SIGNALING+0.180
- KRAS_SIGNALING_DN+0.170
- NOTCH_SIGNALING+0.160
- IL6_JAK_STAT3_SIGNALING+0.150
- P53_PATHWAY+0.150
- MYC_TARGETS_V2+0.130
- GLYCOLYSIS+0.120
- UV_RESPONSE_UP+0.120
Top 10 suppressed
- PROTEIN_SECRETION-0.570
- ANGIOGENESIS-0.420
- TGF_BETA_SIGNALING-0.400
- ANDROGEN_RESPONSE-0.390
- MYC_TARGETS_V1-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- COMPLEMENT-0.280
- UV_RESPONSE_DN-0.280
- MTORC1_SIGNALING-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2681702 | — | — | 0.768 |
| 2 | R84 | — | — | 0.747 |
| 3 | SRR33532821 | — | D | 0.729 |
| 4 | MNG40 | — | — | 0.702 |
| 5 | SRR8613767 | — | E | 0.701 |
| 6 | R147 | — | — | 0.700 |
| 7 | R30 | — | — | 0.685 |
| 8 | SRR12202410 | — | — | 0.681 |
| 9 | 84f39507-9883-4bab-98f9-8bd72d2aee7b | — | — | 0.674 |
| 10 | GSM6454742 | — | D | 0.672 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.020 | Inavolisib | — uncovered |